[1]
|
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660
|
[2]
|
Chen, W., Xia, C., Zheng, R., et al. (2019) Disparities by Province, Age, and Sex in Site-Specific Cancer Burden Attributable to 23 Potentially Modifiable Risk Factors in China: A Comparative Risk Assessment. The Lancet Global Health, 7, e257-e269. https://doi.org/10.1016/S2214-109X(18)30488-1
|
[3]
|
Chen, W., Zheng, R., Baade, P.D., et al. (2016) Cancer Sta-tistics in China, 2015. CA: A Cancer Journal for Clinicians, 66, 115-132. https://doi.org/10.3322/caac.21338
|
[4]
|
Grothey, A., Fakih, M. and Tabernero, J. (2021) Management of BRAF-Mutant Metastatic Colorectal Cancer: A Review of Treatment Options and Evidence-Based Guidelines. Annals of Oncology, 32, 959-967.
https://doi.org/10.1016/j.annonc.2021.03.206
|
[5]
|
Tabbo, F., Pisano, C., Mazieres, J., et al. (2022) How Far We Have Come Targeting BRAF-Mutant Non-Small Cell Lung Cancer (NSCLC). Cancer Treatment Reviews, 103, Article ID: 102335. https://doi.org/10.1016/j.ctrv.2021.102335
|
[6]
|
Dankner, M., Rose, A., Rajkumar, S., Siegel, P.M. and Watson, I. (2018) Classifying BRAF Alterations in Cancer: New Rational Therapeutic Strategies for Actionable Mu-tations. Oncogene, 37, 3183-3199.
https://doi.org/10.1038/s41388-018-0171-x
|
[7]
|
Sun, J., Carr, M.J. and Khushalani, N.I. (2020) Principles of Tar-geted Therapy for Melanoma. Surgical Clinics of North America, 100, 175-188. https://doi.org/10.1016/j.suc.2019.09.013
|
[8]
|
Pickles, O.J., Drozd, A., Tee, L., Beggs, A.D. and Middleton, G.W. (2020) Paradox Breaker BRAF Inhibitors Have Comparable Potency and MAPK Pathway Reactivation to Encorafenib in BRAF Mutant Colorectal Cancer. Oncotarget, 11, 3188-3197. https://doi.org/10.18632/oncotarget.27681
|
[9]
|
Van Cutsem, E., Cervantes, A., Nordlinger, B. and Arnold, D. (2014) Metastatic Colorectal Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 25, iii1-9.
https://doi.org/10.1093/annonc/mdu260
|
[10]
|
Bachet, J.B., Moreno-Lopez, N., Vigano, L., et al. (2019) BRAF Mutation Is Not Associated with an Increased Risk of Recurrence in Patients Undergoing Resection of Colorectal Liver Metastases. British Journal of Surgery, 106, 1237-1247.
https://doi.org/10.1002/bjs.11180
|
[11]
|
Tumeh, P.C., Hellmann, M.D., Hamid, O., et al. (2017) Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. Cancer Immu-nology Research, 5, 417-424.
https://doi.org/10.1158/2326-6066.CIR-16-0325
|
[12]
|
Bouviez, N., Lakkis, Z., Lubrano, J., et al. (2014) Liver Re-section for Colorectal Metastases: Results and Prognostic Factors with 10-Year Follow-Up. Langenbeck’s Archives of Surgery, 399, 1031-1038.
https://doi.org/10.1007/s00423-014-1229-z
|
[13]
|
Primrose, J.N. (2010) Surgery for Colorectal Liver Metastases. British Journal of Cancer, 102, 1313-1318.
https://doi.org/10.1038/sj.bjc.6605659
|
[14]
|
Kopetz, S., Chang, G.J., Overman, M.J., et al. (2009) Improved Sur-vival in Metastatic Colorectal Cancer Is Associated with Adoption of Hepatic Resection and Improved Chemotherapy. Journal of Clinical Oncology, 27, 3677-3683.
https://doi.org/10.1200/JCO.2008.20.5278
|
[15]
|
Chen, K.H., Lin, Y.L., Liau, J.Y., et al. (2016) BRAF Mutation May Have Different Prognostic Implications in Early- and Late-Stage Colorectal Cancer. Medical Oncology, 33, 39. https://doi.org/10.1007/s12032-016-0756-6
|
[16]
|
Poulogiannis, G., Frayling, I.M. and Arends, M.J. (2010) DNA Mismatch Repair Deficiency in Sporadic Colorectal Cancer and Lynch Syndrome. Histopathology, 56, 167-179. https://doi.org/10.1111/j.1365-2559.2009.03392.x
|
[17]
|
Chang, X.N., Shang, F.M., Jiang, H.Y., et al. (2021) Clinicopathological Features and Prognostic Value of KRAS/ NRAS/BRAF Mutations in Colorectal Cancer Patients of Central China. Current Medical Science, 41, 118-126.
https://doi.org/10.1007/s11596-021-2326-1
|
[18]
|
Kopetz, S., Guthrie, K.A., Morris, V.K., et al. (2021) Randomized Trial of Irinotecan and Cetuximab with or without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406). Journal of Clinical Oncology, 39, 285- 294. https://doi.org/10.1200/JCO.20.01994
|
[19]
|
Tabernero, J., Grothey, A., Van Cutsem, E., et al. (2021) Encorafenib plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. Journal of Clinical Oncology, 39, 273-284. https://doi.org/10.1200/JCO.20.02088
|
[20]
|
Weisenberger, D.J., Siegmund, K.D., Campan, M., et al. (2006) CpG Island Methylator Phenotype Underlies Sporadic Microsatellite Instability and Is Tightly Associated with BRAF Muta-tion in Colorectal Cancer. Nature Genetics, 38, 787-793. https://doi.org/10.1200/JCO.20.02088
|
[21]
|
Le, D., Kim, T.W., Van Cutsem, E., et al. (2020) Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatel-lite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164. Journal of Clinical On-cology, 38, 11-19. https://doi.org/10.1200/JCO.19.02107
|
[22]
|
Jang, M.H., Kim, S., Hwang, D.Y., et al. (2017) BRAF-Mutated Colorectal Cancer Exhibits Distinct Clinicopathological Features from Wild-Type BRAF-Expressing Cancer Independent of the Microsatellite Instability Status. Journal of Korean Medical Science, 32, 38-46. https://doi.org/10.3346/jkms.2017.32.1.38
|
[23]
|
Andre, T., Shiu, K.K., Kim, T.W., et al. (2020) Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. The New England Journal of Medicine, 383, 2207-2218. https://doi.org/10.1056/NEJMoa2017699
|
[24]
|
Schadendorf, D., Hodi, F.S., Robert, C., et al. (2015) Pooled Anal-ysis of Long-Term Survival Data from Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Mela-noma. Journal of Clinical Oncology, 33, 1889-1894.
https://doi.org/10.1200/JCO.2014.56.2736
|
[25]
|
Reck, M., Rodriguez-Abreu, D., Robinson, A.G., et al. (2016) Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 375, 1823-1833.
https://doi.org/10.1056/NEJMoa1606774
|
[26]
|
Grassi, E., Corbelli, J., Papiani, G., Barbera, M.A., Gazzaneo, F. and Tamberi, S. (2021) Current Therapeutic Strategies in BRAF-Mutant Metastatic Colorectal Cancer. Frontiers in On-cology, 11, Article ID: 601722.
https://doi.org/10.3389/fonc.2021.601722
|
[27]
|
Overman, M.J., Lonardi, S., Wong, K., et al. (2018) Durable Clini-cal Benefit with Nivolumab plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Meta-static Colorectal Cancer. Journal of Clinical Oncology, 36, 773-779. https://doi.org/10.1200/JCO.2017.76.9901
|